Bristol-Myers Squibb Co (NYSE:BMY) does about 14.95M shares in volume on a normal day but saw 12954924 shares change hands in the recent trading day. The company now has a market cap of 95.42B USD. Its current market price is $46.89, marking an increase of 0.09% compared to the previous close of $46.85. The 52 week high reached by this stock is $63.33 whilst the lowest price level in 52 weeks is $39.35. The script in recent trading has seen the stock touch a high of $68 and a low of $65.
14 analysts observing the Bristol-Myers Squibb Co (BMY) stock have set the 12-month price targets for the company’s shares at between $65 and $68. The consensus objective for the share price is $55.79, suggesting that the stock has a potential upside of 15.95% over the period. The median price target is 29.49% away from the current levels at $66.5.
FactSet Research has provided data showing that 14 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 5 analysts have rated it as a buy and 9 have advised that investors hold their positions. The consensus recommendation rating is Hold and Wall Street’s advice is for investors to Moderate Buy the stock.
Jefferies upgraded its price target at $70.
The current price level is -1.54%, -9.86%, and -13.42% away from its SMA20, SMA50, and SMA200 respectively, with the BMY price moving above the 50-day SMA on current market day. Bristol-Myers Squibb Co (BMY) stock is down -0.70% over the week and -2.11% over the past month. Its price is -17.10% year-to-date and 10.75% over the past year.
Its 12-month price target is $66.5. To reach the target analysts have set, the stock logically needs to grow 15.95 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $65, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $68.
Outstanding shares total 2.04B with insiders holding 0.08% of the shares and institutional holders owning 82.21% of the company’s common stock. The company has a return on investment of 8.35% and return on equity of 31.99%. The price to earnings ratio (P/E ratio) amounts to 17.60 while the forward price to earnings ratio is 7.72. The beta has a value of 0.37. Price to book ratio is 5.49 and price to sales ratio is 2.00.
